OOIR: Observatory of International Research

Papers

(The TQCC of Oncoimmunology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization	97
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	96
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	80
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	63
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	62
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	61
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	59
Ferroptosis: friend or foe in cancer immunotherapy?	58
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	56
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	55
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	55
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	53
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	50
Correction	48
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 ⁺ T cells eradicates peritoneal metastases in mouse models	46
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response	44
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC	41
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer	41
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells	38
STING is significantly increased in high-grade glioma with high risk of recurrence	37
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	37
CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival	37
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis	36
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response	36
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	35

Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas	34
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition	33
Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer	33
CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage	33
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence	33
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma	33
Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid	32
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model	32
Immune sunrise: from the immunome to the cancer immune landscape	31
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab	31
Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue	31
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy	31
Reprogramming monocyte-derived macrophages through caspase inhibition	31
Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy	29
Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34	29
Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery	29
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	28
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination	28
Immunogenic stress induced by local anesthetics injected into neoplastic lesions	28
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation	28
Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling	28
Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis	27
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion	27
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases	27
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 ⁺ T cell function	27
Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer	27
A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors	26
Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade	26
Trial watch: beta-blockers in cancer therapy	26
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T _reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors	26
The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology	26
Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer	26
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy	26
Cell therapy for a rare disease- hairy cell leukemia variant	25
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML	25
Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8 ⁺ T cells towards the center of human lung tumors	25
Spermidine rejuvenates T lymphocytes and restores anticancer immunosurveillance in aged mice	24
Candidate tumor-specific CD8 ⁺ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis	23
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response	23
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors	23
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers	23
Targeting coagulation to unlock antitumor immunity?	23
M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance	22
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response	22
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes	22
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)	22
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy	21
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products	21
Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia	21
Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy	20

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 ⁺ T cells in vivo	20
Mitochondrial DNA transfer between malignant cells and T lymphocytes shapes the cancer-immunity dialogue	20
CD8 ⁺ T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance	20
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma	20
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	20
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)	20
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade	20
Schweinfurthin induces ICD without ER stress and caspase activation	20
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	19
CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies	19
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	19
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer	19
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	19
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	19
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction	18
Metabolic heterogeneity in tumor cells impacts immunology in lung squamous cell carcinoma	18
Cell type-specific induction of ferroptosis to boost antitumor immunity	18
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	18
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer	18
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression	18
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis	18
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro	18
Enriched circulating and tumor-resident TGF-β ⁺ regulatory B cells in patients with melanoma promote FOXP3 ⁺ Tregs	18
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma	18
g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral blood	17
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy	17
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition	17
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis	17
Piezo1 facilitates optimal T cell activation during tumor challenge	17
High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils	17
Small extracellular vesicles: multi-faceted tools for leukemia immune evasion in vivo	17
Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment	17
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration	17
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies	17
LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors	17
Arsenic trioxide as an inducer of immunogenic cell death	17
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden	17
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome	16
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases	16
CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis	16
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function	16
Non-pharmaceutical interventions to optimize cancer immunotherapy	16
QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment	16
CD4 ⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts	15
Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity	15
Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death	15
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?	15
Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis	15
How macrophages use extracellular calreticulin to chase their prey	15
Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I int	14
Tumor-associated macrophages promote intratumoral conversion of conventional CD4 ⁺ T cells into regulatory T cells via PD-1 signalling	14
Cross-disease integration of single-cell RNA sequencing data from lung myeloid cells reveals TAM signature in in vitro model	14
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses	14
An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer	14
Human allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands	14
CD25 ^bright NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression	13
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor	13
Combined tumor-associated microbiome and immune gene expression profiling predict response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer	13
EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by γδT cells preserves neuronal and stem cell integrity	13
The landscape of T-cell engagers for the treatment of follicular lymphoma	13
Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models	13
Immunotherapy approaches for the treatment of diffuse midline gliomas	13
Type I interferon induces cancer stem cells-mediated chemotherapy resistance	13
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer	13
Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer	13
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival	13
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors	13
Metabolic regulation of the mitochondrial immune checkpoint	13
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody	13
Acquired DNA damage repairs deficiency-driven immune evolution and involved immune factors of local versus distant metastases in non-small cell lung cancer	13